[ad_1]
Professor A. Žvirblienė stated that all adverse reactions after vaccines are closely monitored.
“The first message is that all the side effects of the vaccines are being monitored very carefully and that the data is being carefully analyzed. And that allows you to assess those risks. Of course, the frequency of these risks is low, but there is talk of a benefit-risk balance. Then, once the spread of the virus has slowed down a bit, the benefit-risk balance changes. And then the abandonment of vaccines like AstraZeneca can be considered in the long term, ”he said.
The professor explained in the program that the EC is now considering which vaccines will be the most suitable for booster vaccination, to strengthen the immune response next year.
“Vector vaccines like AstraZeneca and Johnson & Johnson would not be very suitable. Because revaccination creates a very strong response against the vector itself.” … On the basis of all these criteria, the European Commission has apparently made such a decision “, the professor explained.
The program participant said that it is difficult to evaluate decision makers.
“It is difficult to judge the decision makers. Because they usually weigh all the pros and cons. And it is easier for me, as a scientist, to reason. (…) Those decisions that are made have a certain resonance in society. This can undermine confidence in vaccines in general if restrictions are adopted. It is difficult for me to assess why some countries make the same decisions and others different, ”said A. Žvirblienė.
The professor said on the show that it might really be worth thinking about giving up the AstraZeneca vaccine.
“It seems to me that we have enough other vaccines to this day. The situation was different a few months ago, when it was really important to vaccinate as many people as possible. So, such a restriction was not very appropriate. But until today, it might be worth considering giving up the AstraZeneca vaccine if there is any disturbing data about the vaccine, ”Prof. A. Žvirblienė assured.
© DELFI / Josvydas Elinskas
The adviser to the Minister of Health, Justina Aleksaitė, said on Monday on the radio news program that there are no recommendations not to vaccinate the entire population with a specific vaccine.
“All vaccines are medicines, so they have secondary and positive effects, the main ones that are essential for us: to protect ourselves against disease. The fact that another disease, capillary permeability syndrome, is included among the side effects of why it is not recommended is not very surprising. Because the vaccine is fairly new, like all other vaccines, research is still ongoing.
We see that this syndrome is quite rare, in Lithuania it does not occur with side effects. Therefore, the Drug Control Service did not give recommendations not to vaccinate the entire population, only a certain group for which it would be more risky ”, said the advisor to J. Areksa Dulkis, J. Aleksaitė, in the program news radio station “Aktualusis interiu”.
He said the efficacy of the vaccine mix is now being studied.
“I think these solutions will come to us in the fall,” said J. Aleksaitė.
A SAM spokeswoman on the program said she was currently thinking about how to continue with the vaccination plan.
“We have a debate on how to continue the vaccination plan in general. And yes, there is a debate that only RNA-based vaccines, Moderna and Pfizer, will be used for further revaccination. But this does not limit the current vaccination with AstraZeneca. This does not remove the possibility of continuing with the additional dose of the vaccine from another platform, it will probably even be promoted, “said the representative of the Ministry J. Aleksaitė in the informative radio program” Interview Aktualusis “.
[ad_2]
